[Molecule based diagnosis].

Hideyuki Akaza; Tomohiko Ichikawa; Takashi Tsuruo; Yasuhiro Shimada; Hisataka Moriwaki; Masaki Mori; Shinzaburo Noguchi; Seigo Nakamura; Nagahiro Saijo; Saburo Sone; Seiji Isonishi; Yasuo Ohashi; Shiro Hinotsu; Mikael von Euler; George Blackedge

PubMed · 14750337

[Molecule based diagnosis].

Hideyuki Akaza·Tomohiko Ichikawa·Takashi Tsuruo·Yasuhiro Shimada·Hisataka Moriwaki·Masaki Mori·Shinzaburo Noguchi·Seigo Nakamura·Nagahiro Saijo·Saburo Sone·Seiji Isonishi·Yasuo Ohashi·Shiro Hinotsu·Mikael von Euler·George Blackedge

View original source ↗Export metadata ↓

Abstract

Based on reviews of the concept of diagnostics and in general and in specific tumour areas it was clear that development of diagnostic procedures involving genomics will allow for much better targeted and tailored treatments in the future. This will result in better efficacy and better tolerability of cancer treatments, but will also allow for progress in prediction, diagnosis and dose selection. Large collaborative projects studying the efficacy and safety of drugs on the genome level is promising to bring important benefits to both patients and the national economy by reducing useless drug therapy. In colorectal cancer there are several genetic defects identified that can act as the target for directed therapy in the future. Expressions of tumour specific antigens open the way for immunological targeted therapies. Developments in the understanding of the genomic basis for resistance to anti-tumour therapy is promising to help targeting patients likely to respond and not develop resistance. A Japanese model is being developed to determine the relative risk of breast cancer of Japanese women. Based on this prevention therapies can be instigated. The last four years have seen the introduction of four novel targeted therapies. If this model should become a standard in the future, much stronger collaboration between academic research and pharmaceutical industry need to develop.

Explore related subjects

Antineoplastic Agents Breast Neoplasms Clinical Trials as Topic Genomics Human Genome Project Humans Male Neoplasms Pharmacogenetics Predictive Value of Tests Prostatic Neoplasms Risk Factors English Abstract Journal Article Multicenter Study Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Hideyuki Akaza, Tomohiko Ichikawa, Takashi Tsuruo, Yasuhiro Shimada, Hisataka Moriwaki, Masaki Mori, Shinzaburo Noguchi, Seigo Nakamura, Nagahiro Saijo, Saburo Sone, Seiji Isonishi, Yasuo Ohashi, Shiro Hinotsu, Mikael von Euler, George Blackedge. 2004. [Molecule based diagnosis].. https://pubmed.ncbi.nlm.nih.gov/14750337/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2021

Deep generative neural network for accurate drug response imputation.

Drug response differs substantially in cancer patients due to inter- and intra-tumor heterogeneity. Particularly, transcriptome context, especially tumor microenvironment, has been shown playing a significant role in shaping the actual treatment outcome. In this study, we develop a deep variational autoencoder (VAE) model to compress thousands of genes into latent vectors in a low-dimensional space. We then demonstrate that these encoded vectors could accurately impute drug response, outperform standard signature-gene based approaches, and appropriately control the overfitting problem. We apply rigorous quality assessment and validation, including assessing the impact of cell line lineage, cross-validation, cross-panel evaluation, and application in independent clinical data sets, to warrant the accuracy of the imputed drug response in both cell lines and cancer samples. Specifically, the expression-regulated component (EReX) of the observed drug response achieves high correlation across panels. Using the well-trained models, we impute drug response of The Cancer Genome Atlas data and investigate the features and signatures associated with the imputed drug response, including cell line origins, somatic mutations and tumor mutation burdens, tumor microenvironment, and confounding factors. In summary, our deep learning method and the results are useful for the study of signatures and markers of drug response.

Antineoplastic Agents↗

PubMed2004

Is there a role for chemotherapy in prostate cancer?

There is evidence from randomised-controlled trials that patients with symptomatic hormone-refractory prostate cancer may experience palliative benefit from chemotherapy with mitoxantrone and prednisone. This treatment is well tolerated, even by elderly patients, although the cumulative dose of mitoxantrone is limited by cardiotoxicity. Treatment with docetaxel or paclitaxel, with or without estramustine, appears to convey higher rates of prostate-specific antigen response in phase II trials, but is more toxic. Large phase III trials comparing docetaxel with mitoxantrone have completed accrual. There is no role for chemotherapy in earlier stages of disease except in the context of a well-designed clinical trial.

Antineoplastic Agents↗

PubMed2004

Mechanism for ribonucleotide reductase inactivation by the anticancer drug gemcitabine.

Gemcitabine (2',2'-difluoro-2'-deoxycytidine, dFdC) is a very promising anticancer drug, already approved for clinical use in three therapeutic indications. It is metabolized intracellularly to 5'-diphosphate (dFdCDP), which is known to be a potent inhibitor of ribonucleotide reductase (RNR). Although several nucleotide analogs show in vitro capacity of RNR inactivation, none has shown the in vivo efficacy of dFdCDP. Accordingly, the experimental data suggests that its mechanism of inhibition is different from the other known RNR suicide inhibitors. Enzyme inhibition in the absence of reductive species leads to complete loss of the essential radical in subunit R2, and formation of a new nucleotide-based radical. Interestingly, however, the presence of the reductants does not prevent inhibition--the radical is not lost but the targeted subunit of RNR becomes R1, which is inactivated possibly by alkylation. We have conducted a theoretical study, which led us to the first proposal of a possible mechanism for RNR inhibition by dFdCDP in the absence of reductants. This mechanism turned out to be very similar to the natural substrate reduction pathway and only deviates from the natural course after the formation of the well-known disulphide bridge. This deviation is caused precisely by the F atom in the beta-face, only present in this inhibitor. The essential radical in R2 is lost, and so is the enzyme catalytic activity. The nucleotide-based radical that constitutes the end product of our mechanism has been suggested in the literature as a possible candidate for the one detected experimentally. In fact, all experimental data available has been reproduced by the theoretical calculations performed here.

Antineoplastic Agents↗